Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

199.33 +2.10 (+1.06%)
Streaming Delayed Price Updated: 3:09 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Why Ascendis Pharma Stock Is Crashing This Week
The FDA put a roadblock in the path to market for Ascendis' hypoparathyroidism drug. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
 
Via Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Analyst Ratings for Ascendis Pharma
 
Via Benzinga
Why Ascendis Pharma Stock Is Plunging Today
A regulatory hiccup is weighing on the biopharma's shares today. 
Via The Motley Fool
Ascendis Pharma Flags Regulatory Delay In US For Its Hypoparathyroidism Candidate
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
 
Via Benzinga
Where Ascendis Pharma Stands With Analysts
 
Via Benzinga
What 9 Analyst Ratings Have To Say About Ascendis Pharma
 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Nasdaq Down 80 Points; VirTra Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping around 80 points on Monday. The Dow traded up 0.89% to 33,571.43 while the NASDAQ fell 0.66% to 12,142.07. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Dow Up Triple Digits As Second Quarter Kicks Off
The Dow Jones Industrial Average is up 146 points midday to kick off the second quarter, while the S&P 500 Index inches lower, and the Nasdaq Composite sits firmly in the red. 
Via Talk Markets
Analyst Ratings for Ascendis Pharma
 
Via Benzinga
Why Heska Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Nogin, Inc. (NASDAQ: NOGN) shares surged 172.4% to $7.41. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 101% to $14.24 after climbing 50% on Friday. 
Via Benzinga
Crude Oil Jumps Over 6%; OncoSec Medical Shares Plummet
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday. The Dow traded up 0.58% to 33,468.38 while the NASDAQ fell 0.96% to 12,104.67. The... 
Via Benzinga
Tesla, NIO And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Ascendis Stock Plunges As FDA Identifies Deficiencies In Company's New Drug Application
The FDA decision prevents Ascendis from labeling and marketing the new drug application for TransCon PTH. ASND stock plunged 
Via Investor's Business Daily
ASND LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
The company is testing a drug for children with achondroplasia, a cause of dwarfism. 
Via Investor's Business Daily
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch... 
Via Talk Markets
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.